- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
MSN Laboratories gets CDSCO panel nod to manufacture, market Icatibant Injection
![MSN Laboratories gets CDSCO panel nod to manufacture, market Icatibant Injection MSN Laboratories gets CDSCO panel nod to manufacture, market Icatibant Injection](https://medicaldialogues.in/h-upload/2022/10/22/750x450_188899-msn-new.webp)
New Delhi: Directing that the drug should be sold by retail under the prescription of the designated medical specialist only, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to MSN Laboratories to market and manufacture Icatibant Injection 30mg/3ml (10mg/ml) which is used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE)
HAE is a rare disease characterized by an absent or dysfunctional C1 esterase inhibitor molecule (C1INH). C1INH is an important regulator in the metabolic pathways of complement, kinin-kallikrein and coagulation factors. The symptoms of the disease are due to local accumulations of bradykinin caused by excessive activation of the complement and kinin pathways as a result of the C1INH deficiency.
At the recent SEC meeting for Pulmonary held on 4th November 2022, the expert panel reviewed the raw data of the in-vitro comparative evaluation report of test drug vs innovator drug products presented by drug maker MSN Laboratories.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.